Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2023 financial results after the Nasdaq Global Market closes on Tuesday, May 2, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2023 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarept.

Sarepta Therapeutics to Announce First Quarter 2023 Financial Results

Alnylam Pharmaceuticals

Apellis Pharma

argenx

Ascendis Pharma

BioMarin Pharmaceutical

Amicus Therapeutics

Horizon Pharma

Madrigal Pharmaceuticals

United Therapeutics

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

These Are the Top 10 Holdings of Avoro Capital Advisors

Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.

Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy

WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public.

ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

A report raised questions about the chances for approval of the company's gene therapy to treat Duchenne muscular dystrophy.

Sarepta Therapeutics Tumbles on Gene Therapy Drama

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares took a beating Thursday as Stat News reported that reviewers at the US Food and Drug Administration (FDA) were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by the company. The “non-binding conclusion" prompted FDA official Peter Marks to intervene earlier this year and schedule an advisory meeting on May 12, Stat said citing three people with direct knowledge of the agency deliberations.

Sarepta Therapeutics shares fall as report says FDA almost rejected its gene therapy

Several FDA staffers were leaning toward rejecting a highly watched gene therapy from Sareptas, according to a report Thursday that sent SRPT stock into a dive. The post Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy appeared first on Investor's Business Daily.

Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy

Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs. According to these reports, regulators at the FDA were originally planning to reject the company's request for approval of SRP-9001.

Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?

Sarepta Therapeutics Inc. stock SRPT, -1.02% slid 11% in premarket trade Thursday, after a report said the U.S. Food and Drug Administration was leaning toward rejecting the company's experimental gene therapy for Duchenne muscular dystrophy.

Sarepta stock slides 11% premarket on report FDA was leaning toward rejecting its gene therapy for Duchenne muscular dystrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the date of the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA) is May 12, 2023. The advisory committee meeting will be hosted as a virtual meeting.

Sarepta Therapeutics Announces that the Date of the Advisory Committee Meeting for SRP-9001 will be May 12, 2023

NEW YORK , April 6, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sarepta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

SRPT LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

Regeneron Pharmaceuticals

An experimental new gene therapy from Sarepta Therapeutics has an upcoming date with the Food and Drug Administration and a panel of independent experts. An approval decision coming in June could extend patent-protected exclusivity for Regeneron's biggest revenue stream.

2 Top Growth Stocks That Could Soar This Spring

Citi analyst Neena Bitritto-Garg initiates coverage on shares of Sarepta with a Buy rating.

Sarepta Stock Has $30 to $40 Upside if Panel on Gene Therapy Drug Positive, Says Analyst

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) on behalf of Sarepta stockholders. Our investigation concerns whether Sarepta has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action.

SAREPTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Sarepta Therapeutics, Inc. on Behalf of Sarepta Stockholders and Encourages Investors to Contact the Firm

NEW YORK , March 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sarepta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

SRPT INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

Axsome Therapeutics

Travere Therapeutics

Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.

3 Up-and-Coming Growth Stocks to Buy Right Now

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential violations of U.S. federal securities laws by Sarepta Therapeutics, Inc. (NASDAQ: SRPT) focused on whether Sarepta and certain of its top executive officers made false and misleading statements and/or failed to disclose material information to investors.

SRPT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sarepta Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

NEW YORK--(BUSINESS WIRE)---- $SRPT #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/srpt. The investigation concerns whether Sarepta has violated federal securities laws.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Sarepta Therapeutics, Inc. (SRPT) Investigation

The middle of March may be when many people celebrate St. Patrick's Day, but it was an unlucky time for Sarepta Therapeutics (NASDAQ: SRPT). Unfortunately, the United States Food and Drug Administration recently announced they need time to investigate data on the company's new Duchenne Muscular Dystrophy (DMD) treatment.

Why did Sarepta Therapeutics Stock Plummet?

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?

NEW YORK , March 20, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from allegations that Sarepta may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sarepta securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT

Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.

Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001

FedEx

Markets were slightly lower at the open on Friday as investors prepared for expiration of stock options and futures contracts. FedEx shares moved higher following the delivery giant's latest financial report.

The 2 Stocks to Watch on a Nail-Biter Friday

Sarepta Therapeutics (NASDAQ: SRPT ) stock is sliding lower on Friday after the company announced an advisory committee meeting with the FDA. According to a press release, the company will meet with the FDA prior to May 29, 2023, to discuss the development of SRP-9001.

Why Is Sarepta Therapeutics (SRPT) Stock Down 20% Today?

In a surprise decision, the FDA will hold an advisory committee to discuss Sarepta's gene therapy, and SRPT stock tanked Friday. The post Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy appeared first on Investor's Business Daily.

News for Sarepta Therapeutics Stock (SRPT)